Misty Eleryan, MD
MOHS-Micrographic Surgery · Marina del Rey, CANPI 1588989412
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,570 of the $6,708 with a category attached, or 68.1%. 16 manufacturers reported payments, led by Galderma Laboratories, L.p. at 36.1% of the total. Reporting peaked in 2023 at $2,723 and has fallen 97.5% since, to $69 in 2025.
Across 61 payments — averaging $109.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$2K
- Amgen$2K
- Bristol Myers Squibb$1K
- AbbVie$368
- Sun Pharmaceutical Industries Inc.$188
- Sanofi$152
- plus $518 from 10 others
What the payments were for
- Consulting fees$4,57068%
- Travel & lodging$4777%
- Food & beverage$1,56723%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 9 | $2,424 |
| Amgen | 5 | $1,747 |
| Bristol Myers Squibb | 2 | $1,311 |
| AbbVie | 18 | $368 |
| Sun Pharmaceutical Industries Inc. | 4 | $188 |
| Sanofi | 2 | $152 |
| Lilly USA, LLC | 4 | $88 |
| Novartis | 3 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $83 |
| Pfizer | 4 | $78 |
| LEO Pharma Inc. | 2 | $69 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Incyte Corporation | 1 | $24 |
| Verrica Pharmaceuticals Inc. | 1 | $18 |
| Dermavant Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,708 in reported general payments places this provider in the 75th percentile of 144 mohs-micrographic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $66,324 |
| Fluorouracil | 16 | $1,120 |
| Cephalexin | 28 | $409 |
| Triamcinolone Acetonide | 33 | $376 |
| Ketoconazole | 27 | $338 |
| Mupirocin | 35 | $230 |
| Clobetasol Propionate | 11 | $225 |
| Doxycycline Hyclate | 17 | $186 |
| Hydrocortisone | 21 | $110 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Marina del Rey
- Sarah ArronBurlingame$98K
- Daniel Zelacla Jolla$43K
- Ralph MasseySanta Monica$38K
- Michael MortazieOrange$29K
- Sumaira AasiStanford$27K
- Andrea WilleySacramento$21K
- Benjamin Kelleyla Jolla$20K
- Frank NoodlemanSaratoga$19K
- Howard FeinRolling Hills Estates$19K
- Joanna ChanLong Beach$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.